Expert Forum on Bladder Cancer: Bladder-sparing treatment
“We need better tests and better biomarkers to try to determine who still has residual cancer, even though they look like they don't,” says Christopher B. Anderson, MD, MPH.
EP: 1.Expert Forum on Bladder Cancer: The BCG shortage
EP: 2.Expert Forum on Bladder Cancer: Bladder-sparing treatment
EP: 3.Expert Forum on Bladder Cancer: Nadofaragene Firadenovec for BCG-unresponsive NMIBC
EP: 4.Expert Forum on Bladder Cancer: Recent FDA approvals
EP: 5.Expert Forum on Bladder Cancer: Recent Innovations
EP: 6.Expert Forum on Bladder Cancer: Future Innovations
In this video, Sam S. Chang, MD, MBA, Chad R. Ritch, MD, MBA, FACS,and Christopher B. Anderson, MD, MPH, discuss the most recent guidelines and research regarding bladder-sparing techniques for patients with muscle-invasive and non–muscle invasive bladder cancer. This discussion is part of a larger forum on bladder cancer.
Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
